CLEC3B (C-Type Lectin Domain Family 3 Member B)

Collectively, these findings establish estrogen as a key modulator of CAF heterogeneity and highlight a novel mechanism of tumor-stroma cross-talk with potential therapeutic implications for stroma-directed interventions in pancreatic cancer. See related article by Manoukian et al., p. 571.

It further reveals that SRPX2 driven anoikis resistance, mediated through the FAK/AKT-IL-6 axis, facilitates peritoneal metastasis. These findings provide new directions for prognostic assessment and therapeutic strategies in gastric cancer.

This multi-omics study reveals a panel of eight circulating proteins with diagnostic performance superior to that of AFP and independent prognostic value in HCC, nominating NENF as a causal biomarker for disease progression and survival.

Low-risk patients showed higher immune infiltration, lower TIDE scores (suggesting better immunotherapy response), and reduced sensitivity to Axitinib/Gefitinib. Single-cell analysis implicated fibroblasts and myeloid cells in high-risk profiles, with activated MIF/TGF-β pathways. This integrated transcriptomic and single-cell model predicts LUAD prognosis and immune landscape, guiding personalized therapy.

Estrogen production in PDAC was fueled by the catabolism of stroma-derived branched chain amino acids, which ultimately resulted in the production of steroid hormone precursors. Together, these data reveal important hormone-driven factors that limit tumor progression by reprogramming the tumor microenvironment and provide leads for therapy development for PDAC.

In summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.

The use of T cell proliferation-based molecular subtyping and related predictive signatures can enable the effective prognostic assessment of HCC patients. KRT17 may also hold promise as a target for therapeutic interventions in the cancer type.

The identified prognostic genes also play significant roles in immune cell infiltration in LUAD. This study provides new theoretical references for subsequent in-depth research on LUAD.

The study highlights NTRK2, COL14A1, SCN4B, ATP1A2, SLC17A7, SLIT3, COL7A1, CLDN4, CLEC3B, ADCYAP1R1 and MFAP4 as crucial genes associated with GBC. SLIT3, COL7A1 and CLDN4 serve as highly predictive biomarkers, and findings can improve early diagnosis and prognosis, aiding clinical decision-making.

The differential changes of AOC3, CAT, CLEC3B, SEPP1, and HBB protein were proven as early molecular events in lung tumorigenesis. The screening models of lung cancer based on the novel protein markers and traditional tumor markers might be applied for the screening of high-risk individuals.

This study explores the potential of PD-1-modified multifunctional nanovesicles (NVs) loaded with 5-azacytidine (5-Aza) for NSCLC treatment...This synergistic strategy of epigenetic modulation and immune activation offers a promising avenue for NSCLC management. These findings contribute valuable insights into developing targeted nanotherapeutics for effective NSCLC treatment.